BCAL Diagnostics (ASX:BDX) Interest Income : A$0.03 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. BCAL Diagnostics's interest income for the six months ended in Dec. 2023 was A$0.00 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.03 Mil.

BCAL Diagnostics Interest Income Historical Data

The historical data trend for BCAL Diagnostics's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Interest Income Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Interest Income

0.02

0.06

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Income	Get a 7-Day Free Trial			-	0.02	0.03	0.03	-

BCAL Diagnostics Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.03 Mil.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.